|
1) Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003; 299: 1713-6
|
|
|
|
2) Barnard AL, Igakura T, Tanaka Y, et al. Engagement of specific T-cell surface molecules regulates cytoskeletal polarization in HTLV-1-infected lymphocytes. Blood. 2005; 106: 988-95
|
|
|
|
|
|
3) Manel N, Kim FJ, Kinet S, et al. The ubiquitous glucose transporter GLUT-1 is a recepton for HTLV. Cell. 2003; 115: 449-59
|
|
|
|
|
|
4) Takenouchi N, Jones KS, Lisinski I, et al. Glut1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J Virol. 2007; 81: 1506-10
|
|
|
|
|
|
5) Jones KS, Fugo K, Petrow-Sadowski C, et al. Human T-cell eukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J Virol. 2006; 80: 8291-302
|
|
|
|
|
|
6) Ghez D, Lepelletier Y, Lambert S, et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol. 2006; 80: 6844-54
|
|
|
|
|
|
7) Nobuhara Y, Usuku K, Saito M, et al. Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-I-associated neurological disease. Immunogenetics. 2006; 57: 944-52
|
|
|
|
|
|
8) Sabouri AH, Saito M, Usuku K, et al. Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between iranian and japanese HTLV-1-infected individuals. J Gen Virol. 2005; 86: 773-81
|
|
|
|
|
|
9) Oh U, Grant C, Griffith C, et al. Reduced foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus type 1 infection. J Infect Dis. 2006; 193: 1557-66
|
|
|
|
|
|
10) Yamano Y, Takenouchi N, Li HC, et al. Virus-induced dysfunction of CD4＋CD25＋ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest. 2005; 115: 1361-8
|
|
|
|
|
|
11) Porto AF, Santos SB, Muniz AL, et al. Helminthic infection down-regulates type 1 immune responses in human T cell lymphotropic virus type 1 (HTLV-1) carriers and is more prevalent in HTLV-1 carriers than in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2005; 191: 612-8
|
|
|
|
|
|
12) Narikawa K, Fujihara K, Misu T, et al. CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-alpha. J Neuroimmunol. 2005; 159: 177-82
|
|
|
|
|
|
13) Lezin A, Olindo S, Oliere S, et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: A new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis？ J Infect Dis. 2005; 191: 1830-4
|
|
|
|
|
|
14) Umehara F, Nagatomo S, Yoshishige K, et al. Chronic progressive cervical myelopathy with HTLV-I infection: Variant form of HAM/TSP？ Neurology. 2004; 63: 1276-80
|
|
|
|
|
|
15) Vine AM, Witkover AD, Lloyd AL, et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2002; 186: 932-9
|
|
|
|
|
|
16) Umehara F, Nose H, Saito M, et al. Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy. J Neurovirol. 2007; 13: 260-7
|
|
|
|
|
|
17) Silva MT, Araujo A. Spinal cord swelling in human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis: Magnetic resonance indication for early anti-inflammatory treatment？ Arch Neurol. 2004; 61: 1134-5
|
|
|
|
|
|
18) Bagnato F, Butman JA, Mora CA, et al. Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. J Neurovirol. 2005; 11: 525-34
|
|
|
|
|
|
19) Umehara F, Tokunaga N, Hokezu Y, et al. Relapsing cervical cord lesions on MRI in patients with HTLV-I-associated myelopathy. Neurology. 2006; 66: 289
|
|
|
|
|
|
20) Oh U, Yamano Y, Mora CA, et al. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol. 2005; 57: 526-34
|
|
|
|
|
|
21) Matsuzaki T, Saito M, Usuku K, et al. A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci. 2005; 237: 75-81
|
|
|
|
|